Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Evan Dimmer who wrote (3296)	12/10/1997 4:24:00 PM
From: Steve Childs	Respond to of 23519

From the Asensio release. Who's the scripts expert here? Dr. Bond, is that you? I forwarded this to the company and strongly suggested they need to respond to this release immediately, on the wires. I hope if they do they will also do some bashing of their own about Asensio. In letters dated October 10, 1997 and October 17, 1997 Asensio & Company, Inc. advised Vivus, Inc. (Nasdaq: VVUS - news) that it had reviewed certain of IMS America's Pharmaceutical Industry Research Data pertaining to the sales of Vivus' Muse product. In particular, Asensio & Company reviewed IMS' National Prescription Audit (''NPA'') data for new and refill Muse prescriptions for the six (6) months period ended September 30, 1997 and compared Vivus' reported sales for the same period to the IMS prescription data. As a result, Asensio & Company found that a very significant portion of Vivus' Muse product sales were allegedly sold through outlets not monitored by IMS' NPA service. NPA is the recognized industry leader providing a complete and precise view of the prescription marketplace. Asensio & Company requested a description of Vivus customers not tracked by IMS' NPA audit or other information that could explain the discrepancy. Vivus failed to provide any of the requested information. Asensio & Company believes Vivus' 25% sales drop is a result of poor product performance and early nonrecurring sales to undisclosed sources.

To: Evan Dimmer who wrote (3296)	12/10/1997 4:26:00 PM
From: dan grone	Respond to of 23519

You're being hard-headed, unlike the test participants. Dan

To: Evan Dimmer who wrote (3296)	12/10/1997 4:30:00 PM
From: rt1^	Read Replies (1) \| Respond to of 23519

Ed, <Holding until it hits 20 again! (whenever that is, 10 years?) (Please tell me I am right!) I have no idea Ed, I'm a Day Trader, not an investor. I do wish all the Best of Luck though. rt

To: Evan Dimmer who wrote (3296)	12/10/1997 4:59:00 PM
From: raymond marcotte	Read Replies (1) \| Respond to of 23519

evan, sometimes the most difficult thing to do in this life is to just sit on your hands. $20 is much better than $40. but there are times when you can't afford to hold on! this may be one of them. the press release is fatal. "A study of 123 impotent men treated with Vivus' Muse product at the Centre for Impotence and Fertility in Rome, Italy found that Muse failed to make 121 of the penises rigid. This test's endpoint was very different than Vivus' 1996 study, which used an ''Erection Assessment Scale.'' The Italian study actually measured the rigidity of each penis and concluded that the penises were not hard." surely this is a tough one to get caught up in, but you are better off taking you medicine now. sell on any recovery and invest the balance in something with more solid prospects - like merck, lily, or pfizer. the landscape is littered with companies that never recovered from such a turn of events. we all have had our disasters and incredible misfortunes. it may be good to avoid denial and deal with yours straight on. get proactive and prepare to move on with a good lesson under your belt. the guys that were in at $40 in early october and still waiting will be suffering for a long, long time. ray